Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.16 - $100.0 $99,272 - $62 Million
-620,455 Reduced 31.78%
1,332,140 $204,000
Q2 2022

Aug 15, 2022

BUY
$0.2 - $0.5 $390,519 - $976,297
1,952,595 New
1,952,595 $808,000
Q3 2021

Nov 15, 2021

SELL
$1.11 - $1.7 $110,446 - $169,151
-99,501 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$1.46 - $2.25 $2.9 Million - $4.47 Million
-1,987,834 Reduced 95.23%
99,501 $168,000
Q1 2021

May 17, 2021

BUY
$1.77 - $2.93 $2.21 Million - $3.66 Million
1,250,265 Added 149.36%
2,087,335 $3.74 Million
Q4 2020

Feb 16, 2021

BUY
$2.13 - $3.26 $1.78 Million - $2.73 Million
837,070 New
837,070 $1.79 Million
Q3 2020

Nov 16, 2020

SELL
$1.53 - $3.13 $24,073 - $49,247
-15,734 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$0.48 - $1.75 $7,552 - $27,534
15,734 New
15,734 $24,000
Q2 2019

Aug 14, 2019

SELL
$0.94 - $1.6 $120,172 - $204,548
-127,843 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$0.51 - $1.88 $63,446 - $233,881
-124,405 Reduced 49.32%
127,843 $199,000
Q4 2018

Feb 14, 2019

SELL
$0.39 - $3.47 $155,601 - $1.38 Million
-398,977 Reduced 61.27%
252,248 $108,000
Q3 2018

Nov 14, 2018

SELL
$1.39 - $2.25 $492,887 - $797,838
-354,595 Reduced 35.25%
651,225 $1.38 Million
Q2 2018

Aug 14, 2018

BUY
$1.44 - $2.24 $766,265 - $1.19 Million
532,129 Added 112.34%
1,005,820 $1.45 Million
Q1 2018

May 15, 2018

BUY
$1.51 - $2.06 $592,531 - $808,354
392,405 Added 482.75%
473,691 $777,000
Q4 2017

Feb 14, 2018

BUY
$1.4 - $2.6 $113,800 - $211,343
81,286
81,286 $130,000

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.